Global Smart Inhalers Market Outlook to 2027 – Rising Incidence of Chronic Respiratory Diseases Driving Growth –

DUBLIN–(BUSINESS WIRE)–The “Global Smart Inhalers Market Size, Share and Trends Analysis Report by Product, By Disease Indication, by Distribution Channel, by Regional Outlook and Forecast, 2021-2027” report has been added to from offer.

The global smart inhaler market size is expected to reach USD 414.4 million by 2027, growing the market at a CAGR of 24.9% during the forecast period.

Smart inhalers are inhalation devices that deliver a range of medications. Inhalers contain anticholinergics, glucocorticoids, insulin and beta-agonists, which are used to treat and prevent breathing disorders such as asthma and chronic obstructive pulmonary disease (COPD). When sensors are placed like a clip on the inhalers to monitor the proper dose per intake and the technique used to inhale the medicine, these inhalers are called smart inhalers. Sensor data is shared with the patient and healthcare professionals to track inhaler usage. The monitored data is then exchanged with their mobile applications via an internet platform using Bluetooth technology, and electronic health records (EHRs) or electronic medical records (EMRs) are thus maintained.

Some smart inhalers have sensors that can identify if a person is in a polluted or pollen-filled environment, give helpful reminders, and indicate if an individual’s inhalation technique needs to be reviewed. Individuals do not need to keep their own records as all inhalers are intended to automatically track frequency of use.

Indoor air pollution in households in both underdeveloped and developing countries is becoming an increasingly prevalent problem with the increase in population of these countries. Respiratory problems such as COPD and asthma are more common among people who live in poor housing and neighborhoods. Particle inhalation occurs when kerosene lamps and portable stoves are used for heating and cooking.

In addition, increasing tobacco use among men and women in high-income countries, along with the increased risk of indoor air pollution, is expected to increase the prevalence of respiratory diseases in both men and women. Smoking, biomass for heating and cooking, and poor ventilation are all sources of indoor pollution in low-income countries. As a result, an increase in indoor pollution is expected to lead to an increase in cases of asthma and COPD, which will boost the market.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic has affected various sectors of the business field. The imposition of various restrictions such as lockdown, ban on cross-border travel, social distancing norm, temporary ban on manufacturing units and ban on imports and exports, have disrupted the supply chain of various goods or products around the world.

Market Drivers:

Increased incidence of chronic respiratory diseases

Asthma is the name of a chronic lung disease that can affect both children and adults. Due to inflammation and tightening of the muscles around the tiny airways, the air channels in the lungs narrow. Asthma patients suffer from symptoms such as coughing, wheezing, shortness of breath and chest tightness. These sensations are transient, however, especially, these symptoms worsen at night and during physical workouts. Asthma symptoms can be exacerbated by other common external and internal factors. Viral infections (colds), dust, smoke, fumes, weather changes, grass and tree pollen, animal fur and feathers, harsh soaps and perfumes are all triggers potentials. The intensity of the effects of triggers can vary from person to person. nobody.

Smart inhalers are more effective than regular inhalers

Smart inhalers are not just simple inhalers, but any electronic device that can share data and track records. With the use of Bluetooth, digital inhalers can be connected to smartphones, enabling dosing reminders and dose monitoring. Additionally, these devices have patient education tools that help reduce dosing errors, which lowers hospitalization and treatment costs. The number of doctor visits by patients using these types of inhalers dropped dramatically. The increase in research and development on smart inhalers is expected to make them more effective and efficient, thereby increasing their demand in the market.

Marketing Restriction Factor:

Smart inhalers are expensive

A smart inhaler costs on average around $99. This varies depending on the brand and the capabilities it offers. Naturally, the more sophisticated the features, the more expensive they are. The same can be said for the cost of smart inhalers, which have sensors built into the device. Only certain medications and specific inhalers are allowed to be used with certain smart inhalers. Therefore, it is essential to double-check the manufacturer’s website or ask the pharmacist for additional information about the inhaler, asthma treatments, and mobile device compatibility. Purchasing medications can be expensive, and purchasing equipment or devices to help manage the disease involves additional expenses.

Market Segments Covered in the Report:

By product

  • Metered dose inhalers (MDI)

  • Dry powder inhalers (DPI)

By disease indication

  • Asthma

  • Chronic Obstructive Pulmonary Disease (COPD)

By distribution channel

  • Hospitals Pharmacies

  • Retail pharmacies

  • Online pharmacies

By geography

  • North America

  • WE

  • Canada

  • Mexico

  • Rest of North America

  • Europe

  • Germany

  • UK

  • France

  • Russia

  • Spain

  • Italy

  • The rest of Europe

  • Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Rest of Asia-Pacific


  • Brazil

  • Argentina

  • United Arab Emirates

  • Saudi Arabia

  • South Africa

  • Nigeria

  • Rest of LAMEA

Main market players

  • Adherium Limited

  • Aptar Group Inc. (Cohero Health Inc.)

  • AstraZeneca, Inc.

  • Cognita Labs, LLC

  • GlaxoSmithKline Plc

  • Novartis AG

  • OPKO Health, Inc.

  • Philip Morris International, Inc. (Vectura Plc Group)

  • Resmed, Inc. (Propeller Health)

  • Teva Pharmaceutical Industries Ltd.

For more information on this report, visit